These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 578932)

  • 1. [Clinical effects of monocomponent insulin and commercial insulin preparations on insulin requiring diabetics (author's transl)].
    Nakashima Y; Oyama H; Tenku A; Matsumura S; Nishida S
    Radioisotopes; 1977 Mar; 26(3):158-62. PubMed ID: 578932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proinsulin and A-component antibodies in diabetics after long-term monocomponent insulin treatment.
    Bruni B; Gamba S; Regis G; Turco GL
    Diabetologia; 1978 Mar; 14(3):165-9. PubMed ID: 566232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treatment with monocomponent semi-lente insulin in diabetes of difficult compensation].
    Barbero L; Gamba S; Zanno C; Regis G; Bruni B
    Minerva Med; 1978 Apr; 69(21):1437-42. PubMed ID: 683547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The antigenicity of various new chromatographically purified depot insulin preparations].
    Graber D; Fankhauser S
    Schweiz Med Wochenschr; 1978 Nov; 108(46):1807-9. PubMed ID: 715418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical experiences with monocomponent insulins].
    Bruni Bocher K; Giolitti A; Turco GL; Benedetto P; Bruni B
    Minerva Med; 1975 Mar; 66(19):909-30. PubMed ID: 1124144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diurnal profiles of serum insulin, C-peptide and blood intermediary metabolites in insulin treated diabetics, their relationship to the control of diabetes and the role of endogenous insulin secretion.
    Asplin CM; Hartog M; Goldie DJ; Alberti KG; Binder C; Faber OK
    Q J Med; 1979 Apr; 48(190):343-60. PubMed ID: 574299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circadian variations in plasma immunoreactive insulin (IRI) and C-peptide concentrations in adult onset (type II) diabetes mellitus.
    Nicolau GY; Haus E; Lakatua DJ; Bogdan C; Petrescu E; Sackett-Lundeen L; Stelea S; Stelea P
    Endocrinologie; 1984; 22(1):3-16. PubMed ID: 6369501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical use of NPH insulin (author's transl)].
    Roesner M; Sauer H
    Dtsch Med Wochenschr; 1976 Jun; 101(23):886-9. PubMed ID: 1269430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circadian profiles of blood glucose and plasma free insulin during treatment with semisynthetic and biosynthetic human insulin, and comparison with conventional monocomponent preparations.
    Castillo M; Nemery A; Verdin E; Lefebvre PJ; Luyckx AS
    Eur J Clin Pharmacol; 1983; 25(6):767-71. PubMed ID: 6363099
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of a new lente insulin on diabetics.
    Ohneda A; Nihei J; Sasaki M
    Diabetes Res Clin Pract; 1990 Jan; 8(2):101-7. PubMed ID: 2307090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin antibodies in diabetics receiving a single type of insulin.
    Mincu I; Cheţa D
    Med Interne; 1982; 20(1):9-13. PubMed ID: 6765628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Long-term clinical results with monocomponent insulin (MC lente) in infantile and juvenile diabetes].
    Bruni KB; Neirotti R; Albonico G; Gamba S; Regis G; D'Adda A; Soldano E; Bruni B
    Ann Osp Maria Vittoria Torino; 1976; 19(16):7-26. PubMed ID: 1027349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Proinsulin and a-component antibodies in diabetics treated with monocomponent and conventional insulin].
    Gamba S; Barbero PL; Bollati C; Castellazzi R; D'Adda A; Bruni B
    Minerva Dietol Gastroenterol; 1979; 25(3):309-14. PubMed ID: 400003
    [No Abstract]   [Full Text] [Related]  

  • 14. [Experiences in the treatment of diabetes with insulins of monocomponent (MC) and monospecies (MS) type].
    Andreani D; Iavicoli M; Colletti A; Menzinger G
    Folia Endocrinol; 1972 Dec; 25(6):516-39. PubMed ID: 4581824
    [No Abstract]   [Full Text] [Related]  

  • 15. Insulin antibodies and clinical complications in diabetics treated for five years with lente or sulfated insulin.
    Little JA; Lee R; Sebriakova M; Csima A
    Diabetes; 1977 Oct; 26(10):980-8. PubMed ID: 561729
    [No Abstract]   [Full Text] [Related]  

  • 16. Circadian variation of serum glucose, C-peptide immunoreactivity and free insulin normal and insulin-treated diabetic pregnant subjects.
    Lewis SB; Wallin JD; Kuzuya H; Murray WK; Coustan DR; Daane TA; Rubenstein AH
    Diabetologia; 1976 Aug; 12(4):343-50. PubMed ID: 964510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Characterisation of activity of a biphasic monocomponent insulin (author's transl)].
    Neubauer M; Althoff PH; Schnabel O; Genrich V; Schöffling K
    Dtsch Med Wochenschr; 1979 Mar; 104(11):384-90. PubMed ID: 421667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Therapeutic qualities of a lente preparation of swine insulins manufactured by Pharmachem].
    Andreev D; Bozadzhieva E; Pampulov L; Penchev I; Uzunova B
    Vutr Boles; 1977; 16(6):59-66. PubMed ID: 341532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The production and characteristics of anti-insulin, anti-A-component and anti-proinsulin antibodies in patients treated with monocomponent or conventional insulin.
    Kawazu S; Kanazawa Y; Miki E; Hayashi M; Sando H; Kajinuma H; Iwamoto Y; Akanuma Y; Kosaka K
    Acta Diabetol Lat; 1979; 16(4):339-51. PubMed ID: 399151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationship between circulating free and bound insulin, insulin antibodies, insulin dosage and diabetic control in insulin treated diabetics.
    Asplin CM; Hartog M; Goldie DJ
    Acta Endocrinol (Copenh); 1978 Feb; 87(2):330-8. PubMed ID: 580135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.